Senti Biosciences, Inc. (SNTI)
USD 4.01
(-22.14%)
USD 4.01
(-22.14%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -52.39 Million | -34.89 Million | -34.63 Million | -24.17 Million | -18.37 Million |
| Net Income | -83.4 Million | -58.22 Million | -55.31 Million | -19.86 Million | -21.15 Million |
| Depreciation & Amortization | 5.24 Million | 3.92 Million | 3.01 Million | 1.98 Million | 1.39 Million |
| Deferred income taxes | -19.94 Million | - | 22 Thousand | 235 Thousand | -329 Thousand |
| Stock-based compensation | 9.67 Million | 16.39 Million | 2.29 Million | 272 Thousand | 205 Thousand |
| Change in working capital | 4.66 Million | 13.9 Million | 615 Thousand | -1.77 Million | 124 Thousand |
| Other non-cash items | 31.37 Million | -10.89 Million | 14.74 Million | -5.02 Million | 1.38 Million |
| Investing Cash Flow | 30.07 Million | -81.95 Million | -5.54 Million | 11.35 Million | 3.75 Million |
| Investments in PPE | -12.03 Million | -41.37 Million | -5.54 Million | -1.16 Million | -1.99 Million |
| Acquisitions | 105 Thousand | - | - | -12.51 Million | - |
| Investment purchases | -17.99 Million | -40.58 Million | - | -446 Thousand | - |
| Sales/Maturities of investments | 60 Million | - | - | 12.96 Million | - |
| Other Investing Activities | 105 Thousand | -40.58 Million | - | 12.51 Million | 5.74 Million |
| Financing Cash Flow | 779 Thousand | 118.55 Million | 68.43 Million | 38.05 Million | 14.01 Million |
| Debt repayment | -108 Thousand | -5.17 Million | -17 Thousand | -8 Million | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | 512 Thousand | 196 Thousand | - | - | - |
| Common Stock Issuance | 887 Thousand | 1.4 Million | 68.45 Million | - | - |
| Other Financing Activities | -108 Thousand | 118.55 Million | -17 Thousand | 38.05 Million | 14.01 Million |
| Accounts receivables | 507 Thousand | -131 Thousand | -395 Thousand | -10 Thousand | 124 Thousand |
| Accounts payables | -290 Thousand | 186 Thousand | -617 Thousand | -324 Thousand | - |
| Inventory | - | - | -205 Thousand | -1.6 Million | - |
| Other working capital | 4.44 Million | 13.84 Million | 1.83 Million | 165 Thousand | - |
| Cash at beginning of period | 57.62 Million | 59.29 Million | 31.03 Million | 5.79 Million | - |
| Cash at end of period | 35.92 Million | 60.98 Million | 59.29 Million | 31.03 Million | 5.79 Million |
| Capital Expenditure | -12.03 Million | -41.37 Million | -5.54 Million | -1.16 Million | -1.99 Million |
| Effect of forex changes on cash | -156 Thousand | - | - | - | 6.41 Million |
| Net cash flow / Change in cash | -21.69 Million | 1.69 Million | 28.25 Million | 25.23 Million | 5.79 Million |
| Free Cash Flow | -64.43 Million | -76.27 Million | -40.17 Million | -25.33 Million | -20.37 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -11.2 Million | -12.11 Million | -18.68 Million | -83.4 Million | -14.94 Million | -18.69 Million |
| Depreciation & Amortization | 1.46 Million | 1.46 Million | 1.47 Million | 5.24 Million | 1.81 Million | 1.21 Million |
| Deferred income taxes | - | - | -3.16 Million | -19.94 Million | 3.71 Million | -380 Thousand |
| Stock-based compensation | -776 Thousand | 1.25 Million | 2.06 Million | 9.67 Million | 409 Thousand | 3.43 Million |
| Change in working capital | 2.38 Million | 70 Thousand | 5.98 Million | 4.66 Million | -583 Thousand | 880 Thousand |
| Other non-cash items | 2.54 Million | 1.41 Million | 5.29 Million | 31.37 Million | -5.78 Million | -123 Thousand |
| Investing Cash Flow | - | -15 Thousand | 101 Thousand | 30.07 Million | 21.14 Million | 18.33 Million |
| Investments in PPE | - | -15 Thousand | -4000.00 | -12.03 Million | -1.85 Million | -3.66 Million |
| Acquisitions | - | - | 105 Thousand | 105 Thousand | - | - |
| Investment purchases | - | - | 17.99 Million | -17.99 Million | - | - |
| Sales/Maturities of investments | - | - | -60 Million | 60 Million | 23 Million | 22 Million |
| Other Investing Activities | - | - | 2.99 Million | - | 23 Million | 22 Million |
| Financing Cash Flow | - | - | 556 Thousand | 779 Thousand | -23 Thousand | 281 Thousand |
| Debt repayment | - | - | -108 Thousand | -108 Thousand | -23 Thousand | -27 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -12.05 Billion | 512 Thousand | - | 12.05 Billion |
| Common Stock Issuance | - | - | 579 Thousand | 887 Thousand | - | 308 Thousand |
| Other Financing Activities | - | - | 12.05 Billion | -108 Thousand | -23 Thousand | 281 Thousand |
| Accounts receivables | -166 Thousand | 21 Thousand | 2.6 Million | 507 Thousand | 445 Thousand | 199 Thousand |
| Accounts payables | -443 Thousand | 389 Thousand | -755 Thousand | -290 Thousand | -420 Thousand | 605 Thousand |
| Inventory | - | - | 872 Thousand | - | -1.19 Million | 319 Thousand |
| Other working capital | 2.99 Million | -340 Thousand | 4.13 Million | 4.44 Million | 583 Thousand | -243 Thousand |
| Cash at beginning of period | 23.72 Million | 35.92 Million | 39.43 Million | 57.62 Million | 40.08 Million | 35.15 Million |
| Cash at end of period | 15.86 Million | 23.72 Million | 35.92 Million | 35.92 Million | 45.82 Million | 40.08 Million |
| Capital Expenditure | - | -15 Thousand | -4000.00 | -12.03 Million | -1.85 Million | -3.66 Million |
| Effect of forex changes on cash | - | - | 2.87 Million | -156 Thousand | 1.52 Million | 12.05 Billion |
| Net cash flow / Change in cash | -7.86 Million | -12.2 Million | -3.5 Million | -21.69 Million | 5.74 Million | 4.93 Million |
| Free Cash Flow | -8.34 Million | -11.69 Million | -7.04 Million | -64.43 Million | -17.23 Million | -17.34 Million |
BRTX
WBTN
KURRF
RMGCF
TEPCY
688233